A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 111 participants.

Also called NCT07188805

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 111 participants (planned count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07188805
  • EU CT 2024-519829-38-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Mexico, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07188805. Randomized; triple masking; primary purpose treatment. Start 2025-11-19 (actual); primary completion 2029-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Acronym
FIORE
Condition
Left Ventricular Systolic Dysfunction
Condition
Heart Failure (Pediatric)
Intervention (Drug)
Finerenone (Kerendia, BAY94-8862)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct07188805
Content hash
17821fb1388534fc6d7c2fe5b843e336020f0c4814118e039e3b6ac97b5d8e64